The Q1FY20 sales, adj. EBITDA and PAT beat our estimates by 7%, 9% and Change in Estimates | Target | Reco 2% respectively. While the injectable business was in line with guidance, its flat growth with sales of US$67m in US injectable, despite seasonal...